BC-23

• Description :

  BC-23 (NSC 45382) is a proteasome inhibitor. BC-23 exhibits good inhibition of CT-L activity of the proteasome and is selective for malignant over normal cells[1][2].

• Product Name Alternative :

  NSC 45382

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Proteasome

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/bc-23.html

• Purity :

  97.37

• Solubility :

  DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  O=S(C1=CC=C(C=C1)NC(C2=O)=C(C(C3=C2C=CC=C3)=O)Cl)(NC4=NC=CC=C4)=O

• Molecular Formula :

  C21H14ClN3O4S

• Molecular Weight :

  439.87

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Lawrence HR, et, al. Synthesis and biological evaluation of naphthoquinone analogs as a novel class of proteasome inhibitors. Bioorg Med Chem. 2010 Aug 1;18 (15) :5576-92.|[2]Zhang Q, et, al. Enhancement of Radiation Sensitivity in Lung Cancer Cells by a Novel Small Molecule Inhibitor That Targets the β-Catenin/Tcf4 Interaction. PLoS One. 2016 Mar 25;11 (3) :e0152407.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [6298-15-3]